ESMO 2023 – low-dose volrustomig hints at a therapeutic window
But efficacy still needs to go up, as several groups try to combine PD-1 and CTLA-4 using differing approaches.
ESMO 2023 – Revolution sets the bar in pan-KRAS inhibition
But efficacy in NSCLC has slipped since the abstract, and a high rate of rash raises eyebrows.
ESMO 2023 – not so fast, Welireg
The Merck & Co drug's first successful phase 3 study might not be all it’s cracked up to be.
ESMO 2023 – GSK sets up Pfizer battle in B7-H4
Early data on Hansoh’s HS-20089 were enough to tempt GSK, but Seagen isn't far behind.
ESMO 2023 – sabestomig has it all to do in TIM-3
Astra manages to avoid the toxicities that scuppered Lilly’s PD-1 x TIM-3 contender, but still needs to dial up sabestomig’s efficacy.
ESMO 2023 – Amgen’s Steap1 project spurs cautious optimism
But toxicity will be closely watched in future trials.
ESMO 2023 – Perla gives Jemperli combos more backing
The numerical survival benefit versus Keytruda underperform’s Merck’s phase 3 study, but there’s a possible reason for that.
